Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
SomnoMed is an Australian-based medical device company specializing in continuous open airway therapy (COAT) devices for sleep-disordered breathing, primarily obstructive sleep apnea (OSA). The company designs, manufactures, and distributes oral appliances as an alternative to CPAP machines, with operations concentrated in North America, Europe, and Asia-Pacific. Revenue growth is driven by increasing OSA diagnosis rates, CPAP intolerance among patients, and expanding reimbursement coverage for oral appliance therapy.
SomnoMed generates revenue through a B2B2C model, selling custom-fitted oral appliances to dental professionals and sleep specialists who prescribe them to OSA patients. The company captures 59.9% gross margins through proprietary device designs, digital workflow software (SomnoDent platform), and manufacturing scale in its Australian facility. Pricing power derives from clinical efficacy data, regulatory clearances (FDA 510(k), CE Mark), and insurance reimbursement codes that validate the therapy. The business benefits from recurring revenue as devices require periodic replacement (typically 2-3 year lifespan) and ongoing patient monitoring generates accessory sales. Competitive advantages include established relationships with over 3,000 dental practices globally, proprietary CAD/CAM manufacturing capabilities, and a library of clinical studies supporting treatment outcomes.
North American device unit sales growth and market penetration rates among dental practices
Insurance reimbursement policy changes, particularly Medicare and major commercial payers expanding oral appliance coverage
Clinical trial results demonstrating efficacy versus CPAP therapy and patient compliance rates
New product launches with enhanced features (e.g., digital impression integration, remote monitoring capabilities)
Competitive dynamics with ResMed's oral appliance division and emerging digital health OSA solutions
Technological disruption from digital therapeutics and AI-driven OSA management platforms that bypass traditional oral appliances
Regulatory changes to reimbursement policies, particularly if CMS or commercial payers tighten coverage criteria for oral appliance therapy versus CPAP
Long-term competitive threat from pharmaceutical interventions for OSA currently in clinical development (e.g., hypoglossal nerve stimulation drugs)
Consolidation among dental practice management organizations potentially shifting negotiating leverage away from device manufacturers
ResMed's dominant position in sleep apnea market with integrated CPAP and oral appliance portfolio creates cross-selling advantages
Commoditization risk as patents expire and lower-cost generic oral appliances enter the market
Direct-to-consumer teledentistry models bypassing traditional dental practice distribution channels
Vertical integration by large dental service organizations developing proprietary oral appliance solutions
Negative net margin of -3.1% and ROE of -7.4% indicate the company is not yet consistently profitable, creating cash burn risk if growth slows
Current ratio of 1.51 provides modest liquidity cushion but limited runway if operating cash flow deteriorates
Small market cap of $0.1B limits access to capital markets for growth investments or acquisition financing
Foreign exchange exposure with Australian manufacturing base and multi-currency revenue streams (USD, EUR, AUD) creates earnings volatility
moderate - OSA treatment is medically necessary but exhibits discretionary characteristics as patients can delay treatment during economic stress. Approximately 80% of OSA cases remain undiagnosed, creating a large addressable market that expands during periods of increased healthcare utilization. Consumer spending on elective medical procedures correlates with employment stability and disposable income, as oral appliances typically require patient co-pays of $500-1,500 even with insurance coverage. The 21.6% revenue growth suggests the company is capturing market share in an expanding category, but recession risk could slow diagnosis rates and patient conversion.
Rising interest rates have modest negative impact through two channels: (1) higher discount rates compress valuation multiples for unprofitable growth companies (current -3.1% net margin), making the 86.6x EV/EBITDA multiple vulnerable to rate-driven multiple compression, and (2) increased financing costs for dental practices purchasing equipment may slow adoption of new oral appliance programs. However, the company's 0.17 debt/equity ratio and positive operating cash flow trajectory limit direct balance sheet exposure to rate increases. The primary impact is valuation-driven rather than operational.
Minimal direct credit exposure as the business model does not involve consumer lending or significant receivables financing. The company sells to established dental practices with low default risk, and insurance reimbursement provides payment certainty for a portion of revenue. However, tightening credit conditions could indirectly impact demand if patients face reduced access to healthcare financing options for out-of-pocket costs or if dental practices curtail capital investments in new treatment modalities.
growth - The 21.6% revenue growth, 71.8% net income growth (from negative base), and 83.7% EPS growth attract growth-oriented investors betting on market share gains in the underpenetrated OSA treatment market. The 1.3x price/sales ratio and 86.6x EV/EBITDA multiple reflect growth expectations rather than current profitability. The 15.9% one-year return and positive momentum (10.9% three-month return) appeal to investors seeking exposure to healthcare innovation and demographic tailwinds (aging population, rising obesity rates driving OSA prevalence).
high - Small-cap healthcare device companies with $0.1B market caps exhibit elevated volatility due to limited liquidity, binary clinical/regulatory events, and sensitivity to quarterly sales execution. The stock likely trades with beta above 1.5, amplifying broader market moves. Earnings announcements, reimbursement policy changes, and competitive product launches can drive 15-25% single-day moves. The negative net margin adds volatility as profitability inflection timing remains uncertain.